Europe Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143402
- Pages: 225
-
Format:
Short Description
Europe Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
Leber congenital amaurosis (LCA) is a part of the spectrum of early-onset retinal dystrophy (EORD). It usually presents in the first few years of life, most often before the age of 1 year. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
Market Segmentation:
Europe leber congenital amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel.
On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others.
On the basis of type, the leber congenital amaurosis market is segmented into diagnosis and therapy.
On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others.
Market Players
The key market players for Europe leber congenital amaurosis market are listed below:
Invitae Corporation
Spark Therapeutics, Inc.
LKC TECHNOLOGIES, INC
CENTOGENE N.V.
Optos, Metrovision,
Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics)
CD Genomics
ProQR Therapeutics
OCUGEN, INC.
MeiraGTx Limited
Coave Therapeutics
IVERIC bio, Inc.
Atsena Therapeutics
Editas Medicine
Eluminex Biosciences
Okuvision
Astellas Pharma Inc.
Allergan (A Subsidiary of Abbvie Inc.)
AGTC
Gyroscope Therapeutics Limited
SparingVision
Kubota Pharmaceutical Holdings Co. Ltd.
REGENXBIO Inc
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET 44
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 DISEASE TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET END USER COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 PIPELINE ANALYSIS FOR EUROPE LEBER CONGENTIAL AMAUROSIS MARKET 66
4.2 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 68
4.3 PESTEL ANALYSIS 71
4.4 PORTERS FIVE FORCES 72
5 EPIDEMIOLOGY 73
6 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 74
6.1 DRIVERS 76
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 76
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 79
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 85
6.2 RESTRAINTS 86
6.2.1 LACK OF QUALIFIED PROFESSIONALS 86
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 87
6.3 OPPORTUNITIES 88
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 88
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 88
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 89
6.4 CHALLENGES 90
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 90
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 90
7 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 91
7.1 OVERVIEW 92
7.2 INFANTILE TYPE 95
7.3 JUVENILE TYPE 95
7.4 OTHERS 96
8 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 97
8.1 OVERVIEW 98
8.2 THERAPY 101
8.2.1 GENE THERAPY 102
8.2.1.1 LUXTURNA 102
8.2.2 RETINAL PROSTHETIC 102
8.2.3 NEUROPROTECTIVE AGENTS 102
8.2.3.1 VITAMIN A PALMITATE 103
8.2.3.2 DOCOSAHEXAENOIC ACID 103
8.2.3.3 LUTEIN 103
8.2.3.4 OTHERS 103
8.2.4 OTHERS 103
8.3 DIAGNOSIS 104
8.3.1 CLINICAL DIAGNOSIS 105
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 105
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 106
8.3.1.1.2 DARK ADAPTOMETRY (DA) 106
8.3.1.2 RETINAL IMAGING 106
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 106
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 107
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 107
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 107
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 107
8.3.1.3 VISUAL FIELD TEST 107
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 107
8.3.1.3.2 MANUAL FIELD TEST 107
8.3.1.4 CLINICAL EYE EXAMINATION 108
8.3.1.4.1 SLIT LAMP 108
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 108
8.3.1.4.3 REFRACTION TEST 108
8.3.1.4.4 DILATION EXAM 108
8.3.1.5 OTHERS 108
8.3.2 GENETIC DIAGNOSIS 109
9 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 110
9.1 OVERVIEW 111
9.2 HOSPITALS 114
9.3 SPECIALITY CLINICS 115
9.4 AMBULATORY SURGICAL CENTERS 116
9.5 HOME HEALTHCARE 117
9.6 OTHERS 118
10 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 119
10.1 OVERVIEW 120
10.2 RETAIL SALES 123
10.2.1.1 HOSPITAL PHARMACIES 124
10.2.1.2 RETAIL PHARMACIES 124
10.2.1.3 OTHERS 124
10.3 DIRECT TENDER 124
11 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 125
11.1 EUROPE 126
11.1.1 GERMANY 133
11.1.2 FRANCE 137
11.1.3 U.K. 141
11.1.4 RUSSIA 145
11.1.5 ITALY 149
11.1.6 SPAIN 153
11.1.7 NETHERLAND 157
11.1.8 SWITZERLAND 161
11.1.9 POLAND 165
11.1.10 TURKEY 169
11.1.11 AUSTRIA 173
11.1.12 HUNGARY 177
11.1.13 NORWAY 181
11.1.14 IRELAND 185
11.1.15 LITHUANIA 189
11.1.16 REST OF EUROPE 193
12 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 194
12.1 COMPANY SHARE ANALYSIS: EUROPE 194
13 SWOT ANALYSIS 195
14 COMPANY PROFILE 196
14.1 SPARK THERAPEUTICS, INC 196
14.1.1 COMPANY SNAPSHOT 196
14.1.2 COMPANY SHARE ANALYSIS 196
14.1.3 PRODUCT PORTFOLIO 197
14.1.4 RECENT DEVELOPMENT 197
14.1.4.1 EU AUTHORIZATION 197
14.2 OPTOS 198
14.2.1 COMPANY SNAPSHOT 198
14.2.2 COMPANY SHARE ANALYSIS 198
14.2.3 PRODUCT PORTFOLIO 199
14.2.4 RECENT DEVELOPMENT 199
14.2.4.1 PRODUCT APPROVAL 199
14.3 CD GENOMICS 200
14.3.1 COMPANY SNAPSHOT 200
14.3.2 COMPANY SHARE ANALYSIS 200
14.3.3 PRODUCT PORTFOLIO 201
14.3.4 RECENT DEVELOPMENT 201
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 202
14.4.1 COMPANY SNAPSHOT 202
14.4.2 REVENUE ANALYSIS 202
14.4.3 COMPANY SHARE ANALYSIS 203
14.4.4 PRODUCT PORTFOLIO 203
14.4.5 RECENT DEVELOPMENTS 203
14.4.5.1 COLLABORATION 203
14.5 LKC TECHNOLOGIES, INC 204
14.5.1 COMPANY SNAPSHOT 204
14.5.2 COMPANY SHARE ANALYSIS 204
14.5.3 PRODUCT PORTFOLIO 205
14.5.4 RECENT DEVELOPMENT 205
14.5.4.1 PRODUCT APPROVAL 205
14.5.5 PRODUCT APPROVAL 205
14.6 AGTC 206
14.6.1 COMPANY SNAPSHOT 206
14.6.2 REVENUE ANALYSIS 206
14.6.3 PRODUCT PORTFOLIO 207
14.6.4 RECENT DEVELOPMENTS 207
14.6.4.1 AGREEMENT 207
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 208
14.7.1 COMPANY SNAPSHOT 208
14.7.2 REVENUE ANALYSIS 208
14.7.3 PRODUCT PORTFOLIO 209
14.7.4 RECENT DEVELOPMENTS 209
14.8 ASTELLAS PHARMA INC. 210
14.8.1 COMPANY SNAPSHOT 210
14.8.2 REVENUE ANALYSIS 210
14.8.3 PRODUCT PORTFOLIO 211
14.8.4 RECENT DEVELOPMENT 211
14.9 ATSENA THERAPEUTICS 212
14.9.1 COMPANY SNAPSHOT 212
14.9.2 PRODUCT PORTFOLIO 212
14.9.3 RECENT DEVELOPMENT 212
14.10 CENTOGENE N.V. 213
14.10.1 COMPANY SNAPSHOT 213
14.10.2 REVENUE ANALYSIS 213
14.10.3 PRODUCT PORTFOLIO 214
14.10.4 RECENT DEVELOPMENT 214
14.10.4.1 PRODUCT LAUNCH 214
14.11 COAVE THERAPEUTICS 215
14.11.1 COMPANY SNAPSHOT 215
14.11.2 PRODUCT PORTFOLIO 215
14.11.3 RECENT DEVELOPMENT 215
14.12 EDITAS MEDICINE 216
14.12.1 COMPANY SNAPSHOT 216
14.12.2 REVENUE ANALYSIS 216
14.12.3 PRODUCT PORTFOLIO 217
14.12.4 RECENT DEVELOPMENTS 217
14.12.4.1 DATA & TRAIL DATA PRESENTATION 217
14.13 ELUMINEX BIOSCIENCES 218
14.13.1 COMPANY SNAPSHOT 218
14.13.2 PRODUCT PORTFOLIO 218
14.13.3 RECENT DEVELOPMENT 218
14.14 GYROSCOPE THERAPEUTICS LIMITED 219
14.14.1 COMPANY SNAPSHOT 219
14.14.2 PRODUCT PORTFOLIO 219
14.14.3 RECENT DEVELOPMENTS 219
14.15 INVITAE CORPORATION 221
14.15.1 COMPANY SNAPSHOT 221
14.15.2 REVENUE ANALYSIS 221
14.15.3 PRODUCT PORTFOLIO 222
14.15.4 RECENT DEVELOPMENTS 222
14.15.4.1 NEW FACILITY 222
14.15.4.2 EXPANSION 222
14.16 IVERIC BIO. 223
14.16.1 COMPANY SNAPSHOT 223
14.16.2 PRODUCT PORTFOLIO 223
14.16.3 RECENT DEVELOPMENT 223
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 224
14.17.1 COMPANY SNAPSHOT 224
14.17.2 REVENUE ANALYSIS 224
14.17.3 PRODUCT PORTFOLIO 225
14.17.4 RECENT DEVELOPMENTS 225
14.18 MEIRAGTX LIMITED 226
14.18.1 COMPANY SNAPSHOT 226
14.18.2 PRODUCT PORTFOLIO 226
14.18.3 RECENT DEVELOPMENT 226
14.19 METROVISION 228
14.19.1 COMPANY SNAPSHOT 228
14.19.2 PRODUCT PORTFOLIO 228
14.19.3 RECENT DEVELOPMENT 228
14.19.3.1 FDA CLEARANCE APPROVAL 228
14.20 OCUGEN INC. 229
14.20.1 COMPANY SNAPSHOT 229
14.20.2 PRODUCT PORTFOLIO 229
14.20.3 RECENT DEVELOPMENT 229
14.21 OKUVISION 230
14.21.1 COMPANY SNAPSHOT 230
14.21.2 PRODUCT PORTFOLIO 230
14.21.3 RECENT DEVELOPMENTS 230
14.21.3.1 APPROVAL 230
14.22 PROQR THERAPEUTICS 231
14.22.1 COMPANY SNAPSHOT 231
14.22.2 PRODUCT PORTFOLIO 231
14.22.3 RECENT DEVELOPMENTS 231
14.23 REGENXBIO INC. 232
14.23.1 COMPANY SNAPSHOT 232
14.23.2 REVENUE ANALYSIS 232
14.23.3 PRODUCT PORTFOLIO 233
14.23.4 RECENT DEVELOPMENTS 233
14.24 SPARINGVISION 234
14.24.1 COMPANY SNAPSHOT 234
14.24.2 PRODUCT PORTFOLIO 234
14.24.3 RECENT DEVELOPMENTS 234
15 QUESTIONNAIRE 235
16 RELATED REPORTS 238
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
